Compare AX & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AX | ADMA |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | 2005 | N/A |
| Metric | AX | ADMA |
|---|---|---|
| Price | $85.00 | $19.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $97.07 | $28.50 |
| AVG Volume (30 Days) | 284.9K | ★ 2.9M |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 205.35 |
| EPS | ★ 7.44 | 0.86 |
| Revenue | ★ $1,202,571,000.00 | $488,559,000.00 |
| Revenue This Year | $16.70 | $22.19 |
| Revenue Next Year | $9.76 | $24.33 |
| P/E Ratio | ★ $11.48 | $23.11 |
| Revenue Growth | 6.69 | ★ 27.63 |
| 52 Week Low | $54.46 | $13.50 |
| 52 Week High | $93.84 | $25.67 |
| Indicator | AX | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 59.73 | 66.02 |
| Support Level | $82.69 | $19.13 |
| Resistance Level | $86.87 | $20.22 |
| Average True Range (ATR) | 2.24 | 0.73 |
| MACD | 0.46 | 0.05 |
| Stochastic Oscillator | 81.24 | 79.44 |
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment. The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.